ALPHAMAB ONCOLOGY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.85 HKD | -1.04% |
|
+12.20% | -57.08% |
| Jun. 05 | ArriVent, Alphamab Unit to Collaborate on Antibody Drug Conjugates For Cancer Treatment | MT |
| Jun. 05 | Alphamab Strikes Deal with Nasdaq-Listed ArriVent to Co-Develop Antibody Drug Conjugates | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 11,223 | 12,811 | 10,383 | 8,963 | 5,823 | 2,551 | - | - |
| Enterprise Value (EV) 1 | 9,585 | 10,969 | 9,089 | 8,240 | 4,994 | 1,966 | 2,178 | 2,226 |
| P/E ratio | -13.5 x | -29.8 x | -25.2 x | -27.3 x | -27.4 x | -8.63 x | -6.83 x | -15.2 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | 71.1 x | 53.7 x | 26.6 x | 10.7 x | 7.16 x | 4.2 x |
| EV / Revenue | - | - | 62.2 x | 49.4 x | 22.8 x | 8.22 x | 6.11 x | 3.67 x |
| EV / EBITDA | -34.9 x | -27.5 x | -24.5 x | -21.8 x | -19.6 x | -6.93 x | -8.87 x | -18.8 x |
| EV / FCF | -24.3 x | -25 x | -19 x | -19.2 x | - | -6.85 x | -6.34 x | -17.7 x |
| FCF Yield | -4.12% | -3.99% | -5.27% | -5.22% | - | -14.6% | -15.8% | -5.64% |
| Price to Book | 2.77 x | 5.64 x | 5.55 x | 5.75 x | - | 1.81 x | 2.24 x | 2.49 x |
| Nbr of stocks (in thousands) | 897,012 | 934,939 | 936,985 | 939,716 | 964,844 | 964,924 | - | - |
| Reference price 2 | 12.51 | 13.70 | 11.08 | 9.538 | 6.035 | 2.671 | 2.671 | 2.671 |
| Announcement Date | 3/31/20 | 3/23/21 | 3/29/22 | 3/31/23 | 3/28/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 146 | 166.8 | 218.8 | 239.1 | 356.2 | 607.3 |
| EBITDA 1 | -274.3 | -398.3 | -370.7 | -377.2 | -254.2 | -283.8 | -245.6 | -118.3 |
| EBIT 1 | -284.7 | -409.4 | -415.6 | -432.4 | -323.3 | -331.7 | -300.5 | -175.9 |
| Operating Margin | - | - | -284.63% | -259.15% | -147.79% | -138.69% | -84.36% | -28.97% |
| Earnings before Tax (EBT) 1 | -832.7 | -427.8 | -412.4 | -325.7 | -210.6 | -298.8 | -377.5 | -170 |
| Net income 1 | -832.7 | -427.8 | -412.4 | -325.7 | -210.6 | -298.8 | -377.5 | -170 |
| Net margin | - | - | -282.44% | -195.22% | -96.26% | -124.95% | -105.96% | -27.99% |
| EPS 2 | -0.9280 | -0.4600 | -0.4400 | -0.3500 | -0.2200 | -0.3097 | -0.3912 | -0.1762 |
| Free Cash Flow 1 | -395.2 | -438 | -478.7 | -430 | - | -287.1 | -343.3 | -125.6 |
| FCF margin | - | - | -327.84% | -257.7% | - | -120.07% | -96.37% | -20.68% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/31/20 | 3/23/21 | 3/29/22 | 3/31/23 | 3/28/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 |
|---|---|---|---|---|---|
| Net sales 1 | 44.9 | - | 146 | - | 113.3 |
| EBITDA | - | - | - | - | - |
| EBIT | -190.2 | -270.1 | -145.5 | - | - |
| Operating Margin | -423.73% | - | -99.67% | - | - |
| Earnings before Tax (EBT) 1 | -324.7 | -267.4 | -145.1 | - | -178.4 |
| Net income 1 | -324.7 | -267.4 | -145.1 | -147.3 | -178.4 |
| Net margin | -723.12% | - | -99.34% | - | -157.5% |
| EPS | -0.3500 | -0.2900 | - | -0.1600 | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 3/23/21 | 8/27/21 | 3/29/22 | 8/31/22 | 3/31/23 |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 1,638 | 1,841 | 1,294 | 724 | 829 | 585 | 373 | 325 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -395 | -438 | -479 | -430 | - | -287 | -343 | -126 |
| ROE (net income / shareholders' equity) | -77.1% | -18.2% | -19.9% | -19% | -13% | -18.2% | -19.7% | -12.2% |
| ROA (Net income/ Total Assets) | -45.2% | -15.6% | -15.4% | -13.5% | -9.9% | -13.1% | -15.2% | -7.96% |
| Assets 1 | 1,841 | 2,747 | 2,672 | 2,411 | 2,127 | 2,276 | 2,485 | 2,136 |
| Book Value Per Share 2 | 4.520 | 2.430 | 2.000 | 1.660 | - | 1.480 | 1.190 | 1.070 |
| Cash Flow per Share 2 | -0.4200 | -0.3700 | -0.3400 | -0.3200 | - | -0.2600 | -0.3200 | -0.0800 |
| Capex 1 | 170 | 90.8 | 158 | 130 | - | 36.6 | 37.3 | 51.9 |
| Capex / Sales | - | - | 108.29% | 77.71% | - | 15.3% | 10.47% | 8.54% |
| Announcement Date | 3/31/20 | 3/23/21 | 3/29/22 | 3/31/23 | 3/28/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
2.671
CNY
Average target price
3.295
CNY
Spread / Average Target
+23.34%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -57.08% | 356M | |
| +52.99% | 59.28B | |
| +41.65% | 40.94B | |
| -6.17% | 40.17B | |
| -5.56% | 28.69B | |
| +10.77% | 26.63B | |
| -22.76% | 18.89B | |
| +30.82% | 12.46B | |
| +1.06% | 12.42B | |
| +25.67% | 12.26B |
- Stock Market
- Equities
- 9966 Stock
- Financials Alphamab Oncology
